Associated Papers
STING: a multifaced player in cellular homeostasis.
Song K et al.
Human Molecular Genetics, 2025
A novel STING1-activating mutation is identified in a patient with childhood-onset systemic lupus erythematosus.
Li T et al.
Clinical Immunology (orlando, Fla.), 2025
Cell biological insights into human STING variants.
Koide S et al.
Cell Structure and Function, 2025
Mosaic TMEM173 gene mutation R284S leading to STING-associated vasculopathy with onset in infancy (SAVI).
Yang Z et al.
International Journal of Dermatology, 2025
Membrane traffic governs the STING inflammatory signalling.
Taguchi T
Journal of Biochemistry, 2023
Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy.
Wu J et al.
Pediatric Rheumatology Online Journal, 2023
Use of Tofacitinib for infant-onset STING-associated vasculopathy: A case report from China.
Shen D et al.
Medicine, 2022
Intracellular Sensing of DNA in Autoinflammation and Autoimmunity.
MacLauchlan S et al.
Arthritis & Rheumatology (hoboken, N.j.), 2022
MITA/STING-mediated antiviral immunity and autoimmunity: the evolution, mechanism, and intervention.
Zhong B et al.
Current Opinion in Immunology, 2022
Clathrin-associated AP-1 controls termination of STING signalling.
Liu Y et al.
Nature, 2022
36261523 (PubMed )
Supplement: 41586_2022_5354_MOESM5_ESM.xlsx › Extended_Data_Fig.5_e_g_i
Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI).
David C et al.
Cells, 2022
The activity of disease-causative STING variants can be suppressed by wild-type STING through heterocomplex formation.
Shindo R et al.
Frontiers in Cell and Developmental Biology, 2022
Case Report: Novel SAVI-Causing Variants in STING1 Expand the Clinical Disease Spectrum and Suggest a Refined Model of STING Activation.
Lin B et al.
Frontiers in Immunology, 2021
Select a paper to view details